Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Onglyza Archives
Print | Email | Share | Comments (2)

FDA Approves Onglyza for Type 2 Diabetes


Aug 15, 2009

Inhibiting DPP-4 increases incretins, which decrease glucagon release, and increases insulin which then decreases glucose. Makes sense?

Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP-4) inhibitor produced by AstraZeneca and Bristol-Myers Squibb, has been approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes

So what exactly are DPP-4 inhibitors, and how do they help people with type 2 diabetes?  DPP-4 inhibitors, like Januvia and now Onglyza, stabilize blood glucose levels by increasing insulin production and decreasing glucose production. As their name would suggest, they manage this by inhibiting DPP-4. When DPP-4 is its usual uninhibited self, it breaks down incretins, which are a group of hormones in the gastrointestinal system. Conversely, when DPP-4 is inhibited, the level of incretins rises. A higher level of incretins is a good thing. Why? Because incretins increase the release of insulin into the blood after a meal even before glucose levels rise, and inhibit the release of glucagon, a hormone that is produced by the pancreas when blood glucose is low.  Inhibiting the release of glucagon is also a good thing. Again, why? Because glucagon raises the level of glucose in the blood by causing the liver to convert glycogen to glucose.

Let's put it another way; inhibiting DPP-4 increases incretins, which decrease glucagon release, and increases insulin which then decreases glucose.  Make sense?  Now say it three times fast.  Now say it backwards.

Yikes!

For a more detailed explanation of DPP-4 inhibitors and incretins, read The Incretin Saga: Mimetics, Enhancers, and Inhibitors.

Source: astrazeneca.com


Categories: Blood Glucose, Diabetes, Diabetes, Food, Insulin, Medications, Onglyza, Products, Research, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 2 comments - Aug 15, 2009

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.